Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

eli lilly nederland b.v. - insuline lispro - suikerziekte - geneesmiddelen die worden gebruikt bij diabetes - voor de behandeling van volwassenen en kinderen met diabetes mellitus die insuline nodig hebben voor de handhaving van de normale glucosehomeostase. liprolog is ook geïndiceerd voor de initiële stabilisatie van diabetes mellitus.

Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artritis, reumatoïde - immunosuppressiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kan als monotherapie of in combinatie met methotrexaat worden gebruikt. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - neoplasmata van de borst - antineoplastische middelen - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

eli lilly nederland b.v. - lasmiditan succinate - migraine stoornissen - pijnstillers - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - colitis, ulcerative - immunosuppressiva - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

eli lilly nederland b.v. - dulaglutide - diabetes mellitus, type 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. voor het onderzoek naar de resultaten met betrekking tot combinaties, effecten op de glycemische controle en cardiovasculaire gebeurtenissen, en de bestudeerde populaties, zie punt 4. 4, 4. 5 en 5.

Olanda - Olandiż - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eli lilly nederland b.v. papendorpseweg 83 3528 bj utrecht - insuline humaan 30 ie/ml ; insuline isofaan, humaan 70 ie/ml - suspensie voor injectie - dinatriumwaterstoffosfaat 7-water (e 339) ; fenol ; glycerol (e 422) ; metacresol ; natriumhydroxide (e 524) ; protaminesulfaat ; water voor injectie ; zinkoxide ; zoutzuur (e 507), - insulin (human)

Olanda - Olandiż - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eli lilly nederland b.v. papendorpseweg 83 3528 bj utrecht - insuline humaan 100 ie/ml - suspensie voor injectie - dinatriumwaterstoffosfaat 7-water (e 339) ; fenol ; glycerol (e 422) ; metacresol ; natriumhydroxide (e 524) ; protaminesulfaat ; water voor injectie ; zinkoxide ; zoutzuur (e 507), - insulin (human)

Olanda - Olandiż - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eli lilly nederland b.v. papendorpseweg 83 3528 bj utrecht - insuline humaan 100 ie/ml - oplossing voor injectie - glycerol (e 422) ; metacresol ; natriumhydroxide (e 524) ; water voor injectie ; zoutzuur (e 507), - insulin (human)

Olanda - Olandiż - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eli lilly nederland b.v. - atomoxetinehydrochloride samenstelling overeenkomend met ; atomoxetine - drank - fosforzuur (e 338) ; kunstmatig frambozensmaakstof ca f-9999 pfc ; natriumbenzoaat (e 211) ; natriumdiwaterstoffosfaat 2-water (e 339) ; natriumhydroxide (e 524) ; propyleenglycol (e 1520) ; sorbitol, vloeibaar, kristalliseerbaar (e 420) ; sucralose (e 955) ; xylitol (e 967), - atomoxetine